Cytocapacity test for the prediction of the hematopoietic...

Details Cytocapacity test for the prediction of the hematopoietic... Cytocapacity test for the prediction of the hematopoietic...

2003-03-24

2010-10-19

Belyavskyi, Michail A (Department: 1644)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S577000

Reexamination Certificate

active

07815921

ABSTRACT:
The present invention relates to a method for determining the hematopoietic cytocapacity of a subject comprising the steps of: (a) determining the amount of leukocytes present in a blood sample obtained from a subject, wherein said subject has been subjected to administration of a single dose of G-CSF and has been maintained for a time sufficient to allow mobilization or release of the leukocytes from hematopoietic production and storage tissues and sites of margination into the blood; and (b) determining the hematopoietic cytocapacity by assessing the amount of leukocytes determined in step (a) with the amount of leukocytes which have been mobilized or released in a control subject wherein said control subject is selected from the group consisting of subjects having (i) a high risk for a disease, disorder or complication associated with high-dose cytotoxic chemotherapy and/or hematopoietic cell transplantation, (ii) an intermediate risk for a disease, disorder or complication associated with high-dose cytotoxic chemotherapy and/or hematopoietic cell transplantation or (iii) a low risk for a disease, disorder or complication associated with high-dose cytotoxic chemotherapy and/or hematopoietic cell transplantation.

REFERENCES:
Breems D. A. et al., “Individual Stem Cell Quality in Leukapheresis Product is Related to the Number of Mobilized Stem Cells,”Bloodvol. 87, No. 12, pp. 5370-5378 (1996).
Copelan E. A. et al., “Analysis of Factors Predicting Speed of Hematopoietic Recovery Using Progenitor Cells Mobilized with Etoposide and G-CSF,”Bloodvol. 94, No. 10, Suppl. 1, Part 1, p. 140a (1999).
Hassan H. T. et al., “Thrombocytopenia After High-Dose Chemotherapy and Autologous Stem Cell Transplantation: An Unresolved Problem and Possible Approaches to Resolve It,”Medline US National Library of Medicine(NLM) vol. 5, No. 4, pp. 407-414 (1996).
Porrata et al., “Early Lymphocyte Recovery Predicts Superior Survival After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma or Non-Hodgkin's Lymphoma, ”Bloodvol. 96, No. 11, Part 1, p. 559a (2000).
Porrata et al., “Early Lymphocyte Recovery Predicts Superior Survival After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma or Non-Hodgkin's Lymphoma, ”Bloodvol. 98, No. 3, pp. 579-585 (2001).
Sola C. et al., “Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements After High-Dose Chemotherapy,”Elsevier Science Publishersvol. 4, No. 3 pp. 195-209 (2002).
Arseniev et at., “Transient Increase of Leukocytes After Transplantation of Expanded and Nonexpanded Allogeneic CD34+ Blood Cells is of Host Origin,”Blood; 89:1116-1118 (1997).
Asano, “Human Granulocyte Colony-Stimulating Factor: Its Basic Aspects and Clinical Applications,”The American Journal of Pediatric Hematology/Oncology; 13:400-413 (1991).
Attal et al., “A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma,”N. Engl J Med; 335:91-97 (1996).
Barlogie et al., “Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma,”Blood; 89:789-793 (1997).
Bensinger et al., “Factors That Influence Collection and Engraftment of Autologous Peripheral-Blood Stem Cells,”J Clin Oncol; 13:2547-2555 (1995).
Beyer et al., “Hematopoietic Rescue After High-Dose Chemotherapy Using Autologous Peripheral-Blood Progenitor Cells of Bone Marrow: A Randomized Comparison,”J Clin Oncol; 13:1328-1335 (1995).
Blay et al., “Early Lymphopenia After Cytotoxic Chemotherapy as a Risk Factor for Febrile Neutropenia,”J Clin Oncol; 14:636-643 (1996).
Bodey et al., “Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia,”Ann Intern Med; 64:328-340 (1966).
Bolwell et al., “Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count,”Bone Marrow Transplant; 20:459-463 (1997).
Bronchud et al., In Vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients,Br J Cancer, 58:64-69 (1988).
Chatta et al., “Effects of In Vivo Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor on the Neutrophil Response and Peripheral Blood Colony-Forming Cells in Healthy Young and Elderly Adult Volunteers,”Blood; 84:2923-2929 (1994).
Cox, “Regression Models and Life-Tables,”J. Roy Stat Soc; (B) 34:187-202 (1972).
Dührsen et al., “Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Hematopoietic Progenitor Cells in Cancer Patients,”Blood; 72:2074-2081 (1988).
Freifeld et al., “A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia During Cancer Chemotherapy,”N Engl J Med; 341: 305-311 (1999).
Fujita et al., “Augmentation of megakaryocytopoiesis within the hematopoietic microenvironment of human granulocyte colony-stimulating factor transgenic mice,”Exp Hematol; 29:1010-1018 (2001).
Gabrilove et al., “Phase I Study of Granulocyte Colony-stimulating Factor in Patients with Transitional Cell Carcinoma of the Urothelium,”J Clin Invest; 82: 1454-1461 (1988).
Herrmann et al., “Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma,”Bone Marrow Transplant, 24:1213-1217 (1999).
Hughes et al., “1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever,”Clin Infect Dis; 25:551-573 (1997).
Kaplan et al., “Nonparametric Estimation From Incomplete Observations,”J Am Stat Ass; 53:457-481 (1958).
Kawakami et al., “Levels of Serum Granulocyte Colony-Stimulating Factor in Patients With Infections,”Blood; 76:1962-1964 (1990).
Kern et al.,“Oral Verus Intravenous Empirical Antimicrobial Therapy for Fever in Patients With Granulocytopenia Who Are Receiving Cancer Chemotherapy,”N Engl J Med; 341:312-318 (1999).
Ketterer et al., “High CD34+Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation,”Blood; 91:3148-3155 (1998).
Klastersky et al., “The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients,”J Clin Oncol; 18:3038-3051 (2000).
Kolbe et al., “Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation,”Bone Marrow Transplant; 19:143-147 (1997).
Kubota et al., “Structural Characterization of Natural and Recombinant Human Granulocyte Colony-Stimulating Factors,”J. Biochem.; 107:486-492 (1990).
Laterveer et al., “Interleukin-8 Induces Rapid Mobilization of Hematopoietic Stem Cells With Radioprotective Capacity and Long-Term Myelolymphoid Repopulating Ability,”Blood; 85(8):2269-75, (1995).
Laterveer et al., “Rapid Mobilization of Hematopoietic Progenitor Cells in Rhesus Monkeys by a Single Intravenous Injection of Interleukin-8,”Blood; 87(2):781-88, (1996).
Lenhoff et al., “Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeoloma: a population-based study,”Blood; 95:7-11 (2000).
Lieschke et al., “Mice Lacking Granulocyte Colony-Stimulating Factor have Chronic Neutropenia, Granulocyte and Macrophage Progenitor Cell Deficiency, and Impaired Neutrophil Mobilization,”Blood; 84:1737-1746 (1994).
Linch et al., “Dose intensificati

Affiliated with

Also associated with

Rating

Cytocapacity test for the prediction of the hematopoietic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytocapacity test for the prediction of the hematopoietic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytocapacity test for the prediction of the hematopoietic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227455